Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Acorda Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +1 vs. Q2 2023
- Shares held
- 159.5K
- +10.2K (+6.8%) vs. Q2 2023
- Total value
- $2.30M
- +$356.6K (+18.4%) vs. Q2 2023
- New holders
- 3
- 5 more added
- Sold out
- 2
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $8.00K |
| Q1 2024 | 17 | $2.13M |
| Q4 2023 | 15 | $2.33M |
| Q3 2023 | 16 | $2.30M |
| Q2 2023 | 15 | $1.94M |
| Q1 2023 | 30 | $3.71M |
| Q4 2022 | 36 | $4.09M |
| Q3 2022 | 36 | $1.91M |
| Q2 2022 | 35 | $3.08M |
| Q1 2022 | 34 | $5.42M |
| Q4 2021 | 34 | $9.48M |
| Q3 2021 | 36 | $14.7M |
| Q2 2021 | 37 | $18.1M |
| Q1 2021 | 37 | $18.0M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Acorda Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 14 | $0 | 0.00% | −502−97.3% | Reduced |
| Qube Research & Technologies Ltd | 1 | $15 | 0.00% | +1 | New |
| JPMorgan Chase & Co | 2 | $29 | 0.00% | +1+100.0% | Added |
| Advisor Group Holdings, Inc. | 2 | $29 | 0.00% | +1+100.0% | Added |
| First Manhattan Co | 3 | $44 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 41 | $615 | 0.00% | +33+412.5% | Added |
| UBS Group AG | 134 | $2.01K | 0.00% | +134 | New |
| Russell Investments Group, Ltd. | 300 | $4.37K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,176 | $17.6K | 0.00% | −100−7.8% | Reduced |
| Deutsche Bank AG | 1,700 | $25.5K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 3,740 | $56.1K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 6,778 | $101.6K | 0.00% | +20.0% | Added |
| Vanguard Group Inc | 10,734 | $160.9K | 0.00% | +10,734 | New |
| Acadian Asset Management LLC | 33,691 | $489.0K | 0.00% | −440−1.3% | Reduced |
| Renaissance Technologies LLC | 46,061 | $690.0K | 0.00% | +500+1.1% | Added |
| Davidson Kempner Capital Management LP | 55,145 | $750.0K | 0.01% | 00.0% | Unchanged |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −204−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |